Patients with Alzheimer's disease (AD) displayed abnormal retinal morphology; however, its potential associations with clinical symptoms, damage of the blood-brain barrier (BBB), and brain structure are unclear.
Objective
To investigate the correlations of retinal morphology with clinical symptoms, BBB damage, and brain structure in AD patients.
Methods
In 97 patients with mild cognitive impairment due to AD (AD-MCI) and dementia due to AD (AD-D), retinal morphology, clinical symptoms, BBB variables in cerebrospinal fluid, and brain structure variables, including medial temporal atrophy (MTA), global cortical atrophy (GCA), and white matter hyperintensities scores were evaluated.
Results
In AD patients, peripapillary superotemporal retinal nerve fiber layer thickness (NFLT) was positively correlated with memory score; the NFLTs of average, inferior, and inferotemporal quadrants were negatively correlated with the level of matrix metalloproteinase 3 level in cerebrospinal fluid; the NFLTs of average, superior, and inferior quadrants were negatively correlated with MTA and GCA scores; superotemporal NFLT was negatively correlated with GCA score. In AD-MCI group, superotemporal NFLT maintained a positive correlation with memory score; the NFLTs in superior and nasoupper quadrants were negatively associated with GCA score. In AD-D group, superonasal NFLT was negatively correlated with matrix metalloproteinase 9 level in cerebrospinal fluid.
Conclusions
In AD patients, thinner peripapillary NFLT mirrors worse memory, significant BBB damage, the atrophy of medial temporal lobe and cortex. In AD-MCI patients, thinner NFLT mirrors worse memory and cortical atrophy. In AD-D patients, thinner NFLT mirrors significant BBB damage.
Koronyo-HamaouiMKoronyoYLjubimovAV, et al.Identification of amyloid plaques in retinas from Alzheimer's patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. Neuroimage2011; 54: S204–S217.
2.
den HaanJMorremaTHJVerbraakFD, et al.Amyloid-beta and phosphorylated tau in post-mortem Alzheimer's disease retinas. Acta Neuropathol Commun2018; 6: 147.
3.
BlanksJCTorigoeYHintonDR, et al.Retinal pathology in Alzheimer's disease. I. Ganglion cell loss in foveal/parafoveal retina. Neurobiol Aging1996; 17: 377–384.
4.
BlanksJCSchmidtSYTorigoeY, et al.Retinal pathology in Alzheimer's disease. II. Regional neuron loss and glial changes in GCL. Neurobiol Aging1996; 17: 385–395.
5.
HintonDRSadunAABlanksJC, et al.Optic-nerve degeneration in Alzheimer's disease. N Engl J Med1986; 315: 485–487.
6.
ChanVTTSunZTangS, et al.Spectral-domain OCT measurements in Alzheimer's disease: a systematic review and meta-analysis. Ophthalmology2019; 126: 497–510.
7.
den HaanJVerbraakFDVisserPJ, et al.Retinal thickness in Alzheimer's disease: a systematic review and meta-analysis. Alzheimers Dement (Amst)2017; 6: 162–170.
8.
López-de-EguiletaALageCLópez-GarcíaS, et al.Ganglion cell layer thinning in prodromal Alzheimer's disease defined by amyloid PET. Alzheimers Dement (N Y)2019; 5: 570–578.
9.
YoonSPGrewalDSThompsonAC, et al.Retinal microvascular and neurodegenerative changes in Alzheimer's disease and mild cognitive impairment compared with control participants. Ophthalmol Retina2019; 3: 489–499.
10.
LarrosaJMGarcia-MartinEBamboMP, et al.Potential new diagnostic tool for Alzheimer's disease using a linear discriminant function for Fourier domain optical coherence tomography. Invest Ophthalmol Vis Sci2014; 55: 3043–3051.
11.
PoloVRodrigoMJGarcia-MartinE, et al.Visual dysfunction and its correlation with retinal changes in patients with Alzheimer's disease. Eye (Lond)2017; 31: 1034–1041.
12.
CunhaJPProençaRDias-SantosA, et al.OCT In Alzheimer's disease: thinning of the RNFL and superior hemiretina. Graefes Arch Clin Exp Ophthalmol2017; 255: 1827–1835.
13.
GaoLLiuYLiX, et al.Abnormal retinal nerve fiber layer thickness and macula lutea in patients with mild cognitive impairment and Alzheimer's disease. Arch Gerontol Geriatr2015; 60: 162–167.
14.
AscasoFJCruzNModregoPJ, et al.Retinal alterations in mild cognitive impairment and Alzheimer's disease: an optical coherence tomography study. J Neurol2014; 261: 1522–1530.
15.
Danesh-MeyerHVBirchHKuJY, et al.Reduction of optic nerve fibers in patients with Alzheimer disease identified by laser imaging. Neurology2006; 67: 1852–1854.
16.
BerishaFFekeGTTrempeCL, et al.Localized retinal nerve fiber layer thinning in patients with early glaucoma or Alzheimer's disease. Invest Ophthalmmol Vis Sci2006; 47: 3379.
17.
PillaiJABermelRBonner-JacksonA, et al.Retinal nerve fiber layer thinning in Alzheimer's disease: a case-control study in comparison to normal aging, Parkinson's disease, and non-Alzheimer's dementia. Am J Alzheimers Dis Other Dement2016; 31: 430–436.
18.
IbrahimYXieJMacerolloA, et al.A systematic review on retinal biomarkers to diagnose dementia from OCT/OCTA images. J Alzheimers Dis Rep2023; 7: 1201–1235.
19.
AlmeidaALMPiresLAFigueiredoEA, et al.Correlation between cognitive impairment and retinal neural loss assessed by swept-source optical coherence tomography in patients with mild cognitive impairment. Alzheimers Dement (Amst)2019; 11: 659–669.
20.
AlberJGoldfarbDThompsonLI, et al.Developing retinal biomarkers for the earliest stages of Alzheimer's disease: what we know, what we don't, and how to move forward. Alzheimers Dement2020; 16: 229–243.
21.
ShiHKoronyoYRentsendorjA, et al.Identification of early pericyte loss and vascular amyloidosis in Alzheimer's disease retina. Acta Neuropathol2020; 139: 813–836.
22.
NationDASweeneyMDMontagneA, et al.Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nat Med2019; 25: 270–276.
23.
MontagneABarnesSRSweeneyMD, et al.Blood-brain barrier breakdown in the aging human hippocampus. Neuron2015; 85: 296–302.
24.
MinersJSKehoePGLoveS, et al.CSF Evidence of pericyte damage in Alzheimer's disease is associated with markers of blood-brain barrier dysfunction and disease pathology. Alzheimers Res Ther2019; 11: 81.
25.
SagareAPBellRDZhaoZ, et al.Pericyte loss influences Alzheimer-like neurodegeneration in mice. Nat Commun2013; 4: 2932.
26.
MontagneANikolakopoulouAMZhaoZ, et al.Pericyte degeneration causes white matter dysfunction in the mouse central nervous system. Nat Med2018; 24: 326–337.
27.
BellRDWinklerEASagareAP, et al.Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron2010; 68: 409–427.
28.
SmithAJDuanTVerkmanAS. Aquaporin-4 reduces neuropathology in a mouse model of Alzheimer's disease by remodeling peri-plaque astrocyte structure. Acta Neuropathol Commun2019; 7: 74.
29.
DuncombeJLennenRJJansenMA, et al.Ageing causes prominent neurovascular dysfunction associated with loss of astrocytic contacts and gliosis. Neuropathol Appl Neurobiol2017; 43: 477–491.
30.
AgrawalSAndersonPDurbeejM, et al.Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis. J Exp Med2006; 203: 1007–1019.
31.
HuQChenCYanJ, et al.Therapeutic application of gene silencing MMP-9 in a middle cerebral artery occlusion-induced focal ischemia rat model. Exp Neurol2009; 216: 35–46.
32.
StomrudEBjörkqvistMJanciauskieneS, et al.Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal Alzheimer's disease. Alzheimers Res Ther2010; 2: 20.
33.
WanWCaoLLiuL, et al.Aβ(1-42) oligomer-induced leakage in an in vitro blood-brain barrier model is associated with up-regulation of RAGE and metalloproteinases, and down-regulation of tight junction scaffold proteins. J Neurochem2015; 134: 382–393.
34.
DeaneRDu YanDSubmamaryanRK, et al.RAGE Mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med2003; 9: 907–913.
35.
ShibataMYamadaSKumarSR, et al.Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest2000; 106: 1489–1499.
36.
MathewSWuDunnDMackayDD, et al.Association of brain volume and retinal thickness in the early stages of Alzheimer's disease. J Alzheimers Dis2023; 91: 743–752.
37.
WangXJiaoBLiuH, et al.Machine learning based on optical coherence tomography images as a diagnostic tool for Alzheimer's disease. CNS Neurosci Ther2022; 28: 2206–2217.
38.
den HaanJJanssenSFvan de KreekeJA, et al.Retinal thickness correlates with parietal cortical atrophy in early-onset Alzheimer's disease and controls. Alzheimers Dement (Amst)2018; 10: 49–55.
39.
AlbertMSDeKoskySTDicksonD, et al.The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the national institute on aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement2011; 7: 270–279.
40.
McKhannGMKnopmanDSChertkowH, et al.The diagnosis of dementia due to Alzheimer's disease: recommendations from the national institute on aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement2011; 7: 263–269.
41.
Garway-HeathDFPoinoosawmyDFitzkeFW, et al.Mapping the visual field to the optic disc in normal tension glaucoma eyes. Ophthalmology2000; 107: 1809–1815.
42.
MurdochIESSMCousensSN. People and eyes: statistical approaches in ophthalmology. Br J Ophthalmol1998; 82: 971–973.
43.
CockrellJRFolsteinMF. Mini-mental state examination (MMSE). Psychopharmacol Bull1988; 24: 689–692.
44.
NasreddineZSPhillipsNABédirianV, et al.The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc2005; 53: 695–699.
45.
GuoQZhaoQChenM, et al.A comparison study of mild cognitive impairment with 3 memory tests among Chinese individuals. Alzheimer Dis Assoc Disord2009; 23: 253–259.
46.
ZhouYLuJGuoQ, et al.Rey-osterriche complex figure test used to identify mild Alzheimer's disease. Chin J Clin Neurosci2006; 14: 501–504.
47.
LinCYChenTBLinKN, et al.Confrontation naming errors in Alzheimer's disease. Dement Geriatr Cogn Disord2014; 37: 86–94.
48.
SebaldtRDalzielWMassoudF, et al.Detection of cognitive impairment and dementia using the animal fluency test: the DECIDE study. Can J Neurol Sci2009; 36: 599–604.
49.
WeiMShiJLiT, et al.Diagnostic accuracy of the Chinese version of the Trail-Making Test for screening cognitive impairment. J Am Geriatr Soc2018; 66: 92–99.
50.
FellowsRPSchmitter-EdgecombeM. Symbol digit modalities test: regression-based normative data and clinical utility. Arch Clin Neuropsychol2019; 35: 105–115.
51.
GuoQSunYMYuanJ. Application of eight executive tests in participants at Shanghai communities. Chin J Behav Med Sci2007; 16: 628–631.
52.
CummingsJLMegaMGrayK, et al.The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology1994; 44: 2308–2314.
53.
KossEWeinerMErnestoC, et al.Assessing patterns of agitation in Alzheimer's disease patients with the Cohen-Mansfield Agitation Inventory. The Alzheimer's Disease Cooperative study. Alzheimer Dis Assoc Disord1997; 11: S45–S50.
54.
StarksteinSEMaybergHSPreziosiTJ, et al.Reliability, validity, and clinical correlates of apathy in Parkinson's disease. J Neuropsychiatry Clin Neurosci1992; 4: 134–139.
55.
KatzSFordABMoskowitzRW, et al.Studies of illness in the aged. The index of ADL: a standardized measure of biological and psychosocial function. JAMA1963; 185: 914–919.
56.
LianTHJinZQuYZ, et al.The relationship between retinal nerve fiber layer thickness and clinical symptoms of Alzheimer's disease. Front Aging Neurosci2020; 12: 584244.
57.
ShiZZhengHHuJ, et al.Retinal nerve fiber layer thinning is associated with brain atrophy: a longitudinal study in nondemented older adults. Front Aging Neurosci2019; 11: 69.
58.
CipolliniVAbdolrahimzadehSTroiliF, et al.Neurocognitive assessment and retinal thickness alterations in Alzheimer disease: is there a correlation?J Neuroophthalmol2020; 40: 370–377.
59.
MammadovaNNepplTKDenburgNL, et al.Reduced retinal thickness predicts age-related changes in cognitive function. Front Aging Neurosci2020; 12: 81.
60.
CasalettoKBWardMEBakerNS, et al.Retinal thinning is uniquely associated with medial temporal lobe atrophy in neurologically normal older adults. Neurobiol Aging2017; 51: 141–147.
61.
MutluUBonnemaijerPWMIkramMA, et al.Retinal neurodegeneration and brain MRI markers: the Rotterdam Study. Neurobiol Aging2017; 60: 183–191.
62.
López-de-EguiletaALópez-GarcíaSLageC, et al.The retinal ganglion cell layer reflects neurodegenerative changes in cognitively unimpaired individuals. Alzheimers Res Ther2022; 14: 57.
63.
den HaanJvan de KreekeJAKonijnenbergE, et al.Retinal thickness as a potential biomarker in patients with amyloid-proven early- and late-onset Alzheimer's disease. Alzheimers Dement (Amst)2019; 11: 463–471.
64.
LakhanSEKirchgessnerATepperD, et al.Matrix metalloproteinases and blood-brain barrier disruption in acute ischemic stroke. Front Neurol2013; 4: 32.
65.
CabanMOwczarekKLewandowskaU. The role of metalloproteinases and their tissue inhibitors on ocular diseases: focusing on potential mechanisms. Int J Mol Sci2022; 23: 4256.
66.
GiebelSJMenicucciGMcGuirePG, et al.Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of the blood-retinal barrier. Lab Invest2005; 85: 597–607.
67.
DrankowskaJKosMKościukA, et al.MMP Targeting in the battle for vision: recent developments and future prospects in the treatment of diabetic retinopathy. Life Sci2019; 229: 149–156.
68.
BrkicMBalusuSVan WonterghemE, et al.Amyloid β oligomers disrupt blood-CSF barrier integrity by activating matrix metalloproteinases. J Neurosci2015; 35: 12766–12778.
69.
SpampinatoSFMerloSSanoY, et al.Astrocytes contribute to Aβ-induced blood-brain barrier damage through activation of endothelial MMP9. J Neurochem2017; 142: 464–477.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
